Biogen
company on 8 shows · 5 statements across 2 episodes · said 30 times in 16 episodes since 2021
All-In 17 
Capital Allocators 5 
Invest Like the Best 2 
No Priors 1 
A Product Market Fit Show 1 
How I Built This 1 
the a16z Podcast 1 
20VC 1
Mentions by year, every show
tap a year for its mentions
All-In 17Capital Allocators 5Invest Like the Best 2How I Built This 1A Product Market Fit Show 1No Priors 120VC 1the a16z Podcast 1
2026 2 mentions in 2 episodes 1 per episode
2025 3 mentions in 3 episodes 1 per episode
2024 1 mention in 1 episode
2023 2 mentions in 2 episodes 1 per episode
2022 5 mentions in 2 episodes 3 per episode
2021 16 mentions in 5 episodes 3 per episode
- E35: Biogen's controversial Alzheimer's drug approval, the billionaire space race, Bitcoin & more
- Moderna and Flagship Pioneering: Noubar Afeyan
- Eli Casdin – Casdin Capital (Manager Meetings, EP.02)
- Private Equity Master 2: John Connaughton – Bain Capital (Capital Allocators, EP.201)
- E36: New FTC Chair, breaking up big tech, government silent spying, Jon Stewart, wildfires & more
- every mention in 2021, scene by scene →
every mention on every show, scene by scene, with the transcript →
5 statements about Biogen, every show
Carnell: Biogen and Lilly Alzheimer's Drugs Slow Cognitive Decline by 30%
“And so, today, we've got some amazing medicines that are both Biogen and Eli Lilly, that if you are late in the disease progression of Alzheimer's, You can start to slow the decline. We can slow that decline by about 30%, and so intuitively that just gives us …”
Chamath: FDA advisory panel voted unanimously against Biogen's Alzheimer's drug
“Three quit, but unanimous vote against approval.”
Friedberg: Antibody therapy costs $5 to make while Biogen charges $56,000
“It costs roughly five dollars to make antibody therapy, just to be clear. So when you make them five bucks roughly is the cost, and they're charging 56,000 dollars for this treatment.”
Chamath predicts Biogen's drug approval will incentivize faster and cheaper competitors
“I think it stands to reason that a lot of people will look at the increase in Biogen's market cap and the profits that Biogen can make over the next 10 or 15 years and say, I will attack that and do that cheaper, faster, better.”